Next 10 |
home / stock / fwbi / fwbi articles
BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clini...
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a cli...
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a cli...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial re...
First Wave BioPharma Inc (NASDAQ:FWBI) has acquired ImmunogenX in an all-stock transaction with the combined company focused on adva...
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executi...
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a cli...
BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a cli...
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clin...
News, Short Squeeze, Breakout and More Instantly...
First Wave BioPharma Inc. Company Name:
FWBI Stock Symbol:
NASDAQ Market:
Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is “ENTO” effective May 17, 2024 BOCA RATON, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Entero Ther...
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...